Skip to main content

Abraham Tzou

Freenome has appointed Abraham Tzou as its VP of regulatory affairs. Tzou will be in charge of regulatory strategy for products developed by Freenome and manage submissions to the US Food and Drug Administration and oversight bodies abroad.  

Tzou joins Freenome after serving as a medical officer at the FDA's Center for Devices and Radiological Health, where he led the clinical evaluation of in vitro diagnostics for cancer screening and prognosis, genetic disorders, and companion tests. During his tenure at the agency, he received commendation for his part in a team that reviewed Exact Sciences' non-invasive, colon cancer screening test Cologuard for parallel review. 

Freenome is developing a non-invasive cancer screening technology that involves genome-wide sequencing and a computational system, called Adaptive Genomics Engine. The company is interested in pursuing Parallel Review for this technology, which if successful, would enable simultaneous FDA approval and a national coverage determination from the Centers for Medicare & Medicaid Services.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.